

## REMARKS

The constructive nature of the Examiner's Official Action of April 2, 2004 is acknowledged with appreciation. It is noted that claims 21-23 are allowed. Claims 17 and 18, having twice been held to constitute no-elected inventions, have been cancelled.

The claims remaining in this application are 21-26. These should appear in the following order: 21-24, 26, and 25.


In accordance with the Examiner's helpful suggestion, claims 24 and 25 have been amended to specify that the pharmaceutical composition comprise "a therapeutically effective amount of" the relevant compound.

Claim 24 has also been amended to limit its dependence to either claim 21 or claim 23, both independent claims. New claim 26, directed to the pharmaceutical composition containing the compound of claim 22, has been added. As such, it corresponds to the subject matter eliminated from claim 24.

It is submitted that no additional fee is due by reason of these amendments. In the event a fee is deemed to be due, however, authority is hereby given to charge such deficiency to Deposit Account No. 13-2165.

It is believed this application is now in condition for formal allowance and favorable action is earnestly solicited.

Respectfully Submitted,  
MATHEWS, COLLINS, SHEPHERD & McKAY, P.A.  
Attorneys for Gerhard Hoefle *et al.*

By:   
Bruce M. Collins  
Reg. No. 20,066

May 10, 2004



MATHEWS, COLLINS, SHEPHERD & McKAY, P.A.  
100 Thanet Circle, Suite 306  
Princeton, NJ 08540  
Tel. (609) 924-8555  
FAX (609) 924-3036